- NCIt
- C3708
Loading cancer entity…
Loading cancer entity…
Clinical trials
349 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01593241 | Therapy De-escalation in Seminoma Stage IIA/B | terminated | Phase 2 | 120 | Swiss Cancer InstituteOTHER | 2 | Feb 13, 2025 | clinicaltrials |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | terminated | Phase 2 | 40 | Rain Oncology IncINDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT02624388 |
| terminated |
| Phase 2 |
| 4 |
| University of VirginiaOTHER |
| 1 |
| May 6, 2024 |
| clinicaltrials |
| NCT00788125 | Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | City of Hope Medical CenterOTHER | 1 | Jul 14, 2023 | clinicaltrials |
| NCT02499952 | Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors | terminated | Phase 2 | 12 | Nasser Hanna, M.D.OTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT03081923 | Durvalumab Alone or With Tremelimumab in Refractory Germ Cell Tumors(APACHE) | terminated | Phase 2 | 36 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | May 14, 2021 | clinicaltrials |
| NCT01055067 | ARQ 197 for Participants With Relapsed or Refractory Germ Cell Tumors | terminated | Phase 2 | 27 | Daiichi SankyoINDUSTRY | 3 | Apr 6, 2021 | clinicaltrials |
| NCT02988843 | Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors | terminated | Phase 2 | 1 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT02689219 | Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors | terminated | Phase 2 | 18 | Nabil AdraOTHER | 1 | Dec 10, 2019 | clinicaltrials |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload | terminated | Phase 2 | 1 | City of Hope Medical CenterOTHER | 1 | Jun 18, 2019 | clinicaltrials |
| NCT00003852 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors | terminated | Phase 2 | 45 | UNICANCEROTHER | 1 | Jun 23, 2016 | clinicaltrials |
| NCT01808534 | Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors | terminated | Phase 2 | 5 | Indiana UniversityOTHER | 1 | Jul 2, 2015 | clinicaltrials |
| NCT00198172 | Phase II Study of Cisplatin Plus Epirubicin Salvage Chemo in Refractory Germ Cell Tumors | terminated | Phase 2 | 37 | Indiana UniversityOTHER | 1 | Jun 3, 2014 | clinicaltrials |
| NCT00042952 | Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer | terminated | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Feb 13, 2025source: clinicaltrials